1. Home
  2. AEYE vs ACRV Comparison

AEYE vs ACRV Comparison

Compare AEYE & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AudioEye Inc.

AEYE

AudioEye Inc.

HOLD

Current Price

$7.24

Market Cap

91.0M

Sector

Technology

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.77

Market Cap

82.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEYE
ACRV
Founded
2005
2018
Country
United States
United States
Employees
116
N/A
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.0M
82.2M
IPO Year
2011
2022

Fundamental Metrics

Financial Performance
Metric
AEYE
ACRV
Price
$7.24
$1.77
Analyst Decision
Strong Buy
Buy
Analyst Count
4
4
Target Price
$14.63
$11.67
AVG Volume (30 Days)
122.9K
506.2K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
30.56
15.13
EPS
N/A
N/A
Revenue
$40,311,000.00
N/A
Revenue This Year
$11.12
N/A
Revenue Next Year
$11.45
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
14.52
N/A
52 Week Low
$5.31
$1.05
52 Week High
$16.39
$3.56

Technical Indicators

Market Signals
Indicator
AEYE
ACRV
Relative Strength Index (RSI) 50.31 46.66
Support Level $6.50 $1.73
Resistance Level $7.42 $1.86
Average True Range (ATR) 0.52 0.12
MACD -0.07 -0.04
Stochastic Oscillator 56.36 25.38

Price Performance

Historical Comparison
AEYE
ACRV

About AEYE AudioEye Inc.

AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences. It generates revenue through the sale of subscriptions for software-as-a-service (SaaS). accessibility solutions.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: